Exact claim · Version 1 · Reviewed 2026-07-23
“All insulin products work the same way and can be swapped freely.”
A verdict on this wording and scope, not a universal grade for Insulin.
01 · Verdict
Misleading
Insulin products differ in timing, concentration, delivery system, and approved labeling. A switch can require clinical oversight and product-specific instructions.
- Evidence basis
- Regulatory or product record
- Scope
- Product-specific insulin formulations, concentrations, delivery systems, and labels.
- Category
- Product equivalence
02 · Primary record
Check the attached evidence
01HUMALOG (insulin lispro) prescribing informationU.S. Food and Drug Administration · Drug label · 2025
Supports the corrective verdict02FDA approves the first rapid-acting insulin biosimilar product for diabetesU.S. Food and Drug Administration · Regulatory · 2026
Supports the corrective verdict
Supports the corrective verdict02FDA approves the first rapid-acting insulin biosimilar product for diabetesU.S. Food and Drug Administration · Regulatory · 2026
Supports the corrective verdict
- Editorial review
- Internal editorial review recorded
- Responsible editor
- Anthony Treviso · Founder and responsible editor
- Clinical-review boundary
- Not independently medically reviewed.